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In this issue of the journal, Dr. Qutaiba Tawfic and his colleagues report their experience with sickle cell disease patients 
(SCD) who were admitted to the Intensive Care 
Unit (ICU) at Sultan Qaboos University Hospital, 
Oman, with various complications of sickle cell 
disease. They studied 49 patients who were admitted 
56 times in the ICU between the years 2005 and 
2009.1 This is an important study which has several 
points worthy of reflection. There is very little 
literature specifically discussing the subject of SCD 
patients who are admitted to an ICU for any SCD 
related complication. The literature typically deals 
with specific complications of SCD, like the acute 
chest syndrome (ACS), vaso-occlusive disorder and 
stroke in these patients, as well as their precipitating 
factors and their management.2–5
The mortality among Tawfic et al.’s, patients 
admitted to the ICU was 16%. They pointed out that 
this figure was lower than the general mortality rate 
of 21.1% in that ICU. 1 However, this is not much of 
a consolation, and it is far from being a reason to 
rejoice. A typical patient admitted to an adult ICU, 
for problems other than SCD, is generally older 
than the patients who were the subject of this study. 
Patients in this study had a median age of only 
27 years and the oldest patient was 52 years old. 
Therefore, the mortality of these patients cannot be 
compared to the mortality of the general adult ICU 
patients. The 16% mortality rate is indeed alarming 
for such a young population and should not be 
readily accepted. It should be a wake-up call as here 
we are dealing with a hereditary blood disorder, 
a killer disease of young adults. The situation is 
probably much worse than that if we include the 
number of children dying from complications of 
SCD in paediatric ICUs across this country, and 
in the general medical and paediatric wards. Child 
statistics were not included in this study, which 
only investigated adults SCD sufferers admitted to 
the ICU. The number of children who die in Oman 
from SCD is not clear and needs further studies. 
How many other children and adults die from SCD 
in their homes in Oman? We truly need to exert 
a more concerted effort to find out the basic facts 
about this disease in Oman. Medical researchers 
need to stop and ponder about the impact of this 
devastating disease on our society.  This needs the 
full attention of the government in general, the 
health services in particular and more expectations 
from patients and non-governmental organisations 
(NGOs). We need answers!
Unfortunately, in the Western world, SCD is 
relatively rare and, hence, there is limited interest 
in research into this disorder. As a result of the 
low incidence, it has neither drawn the attention 
of researchers nor stimulated pharmaceutical 
companies to fund SCD research. There were 
Editor-in-Chief, SQU Medical Journal, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. 
*E-mail: mjournal@squ.edu.om
 الوفيات النامجة عن مرض فقر الدم املنجلي 
يف وحدات العناية املركزة
هل نستطيع عمل ما هو أفضل؟
ملك اللمكي
EDITORIAL
Deaths from Sickle Cell Disease in Intensive 
Care Units
Can we do better?
Lamk  Al-Lamki
Deaths from Sickle Cell Disease in Intensive Care Units 
Can we do better?
134 | SQU Medical Journal, May 2012, Volume 12, Issue 2
a number of clinical research studies on SCD 
published from the United States in the 1990s, many 
of them in reputable journals like New England 
Journal of Medicine,4,5 and other Western journals, 
but there were very few basic research studies into 
this disease. This was followed by a relative lull in the 
2000s, when there was even less research published 
on the subject. Interest had probably waned for 
above-mentioned reasons. Earlier clinical research 
on SCD was into the major complications such as 
ACS, vaso-occlusive disorder, fat embolism, etc. 
and how to manage them. Unfortunately, these 
studies, though worthwhile, contributed little to 
the basic understanding that is needed to reduce 
SCD mortality in countries such as Oman where 
it is prevalent. Thus, Oman and the other Arab 
countries need to be more proactive and themselves 
undertake research into inherited blood disorders 
such as SCD. This would ultimately reduce not only 
mortality and morbidity, but also lessen the social 
and cultural impact of these diseases. For example, 
relationships can be disrupted and marriage plans 
destroyed because of the fear that a potential 
partner has the sickle cell trait or disease.
Tawfic et al. have shown that ACS is the 
most common cause of death in their group of 
patients. This is not an altogether new finding, 
but nonetheless interesting. It is well known that 
ACS is the second commonest cause of SCD 
admissions after painful crisis, and it is the prime 
cause of death killing around 30% of SCD patients. 
Even though ACS was described approximately 20 
years ago,2 and repeatedly studied by others,3,4 we 
have not advanced much in either managing this 
condition, preventing it or dramatically reduce its 
effect, at least not in Arab countries. An aetiological 
contributing factor to ACS is fat embolism, yet little 
research is gone into preventing or combating that 
condition, although there is some evidence that 
hydroxyurea can reduce the recurrence of ACS, and 
reduce its severity.6 
Other patients die of acute stroke, commonly a 
result of vaso-occlusive disease.  Again, we physicians 
as the health guardians of our communities have 
failed our societies by allowing ourselves to remain 
in the dark with respect to the disorders that lead 
to fat embolism, vaso-occlusive disorders, acute 
stroke and ACS, or other complications of SCD. We 
have achieved some progress in infection control, 
which is another major contributing factor to 
the mortality of SCD, and we do use the current 
preventative treatment with hydroxyurea.7 All these 
complications were present in the patients studied 
by Tawfic et al.
In the USA, the prevalence of heterozygous 
carriers of the sickle cell trait is 8% among the 
African Americans.8 This has lead Bruce Mitchell 
to summarise the frustration on the current lack 
of relevant SCD research in USA very concisely: 
“That is where we are: inconclusive data have been 
accepted; inconsistent messages about screening, 
prevention and precaution have been relayed; and 
research into sickle cell trait-associated sudden 
death has not advanced. For many physicians, the 
story stops there.”8 Typically, patients with sickle 
cell trait have about 40% of their haemoglobin 
as haemoglobin-S, but they do not have anaemia 
and so are able to live a normal life. Unfortunately, 
that is not always the case in Africa where life 
expectancy of the 6 million people with sickle cell 
anaemia is only half the normal life expectancy.9 
The World Health Organization (WHO) has 
declared SCD a public health priority. “The WHO 
estimates that 70% of sickle cell anemia deaths in 
Africa are preventable with simple, cost-effective 
interventions, such as early identification of sickle 
cell anemia patients by new born screening and 
subsequent provision of comprehensive care such as 
giving regular prophylaxis such as penicillin V and 
vaccinations. Implementation of comprehensive 
care for SCD patients could lead to improved 
survival through these targeted interventions.”9 If 
70% of SCD deaths are preventable in Africa with 
simple interventions, then we should be able to 
achieve a higher percentage in Oman with all the 
resources and potential that we have in Oman.  If 
the WHO has declared sickle cell disease a public 
health priority in Africa, then why is it not one here 
in Oman? Certainly, we need to pause and ponder—
what do we need to do in Oman for this public 
health priority and to reduce the mortality?  
To start with we need early detection of the 
trait and of the symptoms of the disease. In Africa, 
haemoglobin-S trait is protective against malaria, 
morbidity and mortality, and hence, to some extent, 
it may protect some people from that disease.10 
Although it may be that the sickle cell gene has come 
to Oman for the same reason, this country no longer 
has a major problem with malaria and therefore we 
can afford to rid of SCD. The prevalence of SCD in 
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Oman is generally accepted as 6%.11,12 The incidence 
of the sickle cell disease itself has been reported at 
both 0.2%.12 Clearly, we need much more research 
to obtain more accurate statistics on both, the trait 
and the disease. Recent prospective data from our 
university hospital and Sohar hospital by AlKindi et 
al. indicates the incidence of SCD is about 0.3%.13
The Oman Hereditary Blood Disorder 
Association was established with the aim of improving 
services provided to patients with haemoglobin 
disorders in Oman, including on psychological 
and social levels.11 They raise awareness about 
hereditary blood disorders, including SCD, and 
their effects on the community. This Association 
involves both health professionals and patients 
and, while they are doing a commendable job, they 
need to be more active in lobbying for legislation 
on widespread testing and screening for hereditary 
blood disorders, and in calling for more research. 
The Research Council (TRC) of Oman is currently 
supporting one on-going research project on SCD. 
However, as we have seen, with a mortality rate of 
over 16% from SCD in one Omani ICU, we need 
much more basic research on the aetiology and 
management and, specifically, prevention of all the 
complications. The Association needs to work in 
concert with the Research Council and the Ministry 
of Health to reduce this mortality.
Western countries such as USA and UK have 
managed to lower their overall mortality from 
SCD (not only in the ICU) from 3% to 0.13 per 100 
person years of observation.9 Surely, we need to do 
even better because of the impact this condition 
has on our society. Our doctors have the know-
how but we need more support from the NGOs, 
the public and the Ministry of Health. Oman is 
spending one of the lowest percentages of gross 
domestic product (GDP) on health care, compared 
to most of the world—only just over 2% of GDP, 
compared to 6–12% in other countries and 17.4% in 
the USA.14,15 Oman needs to invest more money to 
support and improve our health system and reduce 
mortality from SCD and other hereditary blood 
disorders. Our health care investment levels should 
not remain at about the lowest in the Gulf region, 
and much lower than most other countries.
So what is the effect of this low health care 
expenditure on SCD? To start with, if we had 
more ICU beds, then we might be able to admit 
patients earlier and therefore, reduce mortality. 
As indicated above, because there is very little in 
the world literature on ICU patients with SCD, 
we have no statistics to compare with our figure 
of 16% mortality, but general medical logic tells us 
that we should be able to lower this rate by earlier 
intervention and better preventative measures. 
Not only should doctors and the ministry be more 
vigilant, but also, the patients need to be better 
educated about the disease, e.g. by presenting 
themselves early to the doctor, as soon as they have 
symptoms that may suggest ACS, such as fever, 
shortness of breath or cough.
The paper published in the New England 
Journal of Medicine in 1994 studied 538 patients 
with SCD and ACS.4 Their mortality was lower with 
only 18 out of their 538 patients dying from ACS 
(3.3%). Certainly, this would indicate that mortality 
from ACS can be reduced with adequate and 
early medical intervention which implies greater 
expenditure and investment in our health services.
In 1999, the National Institutes of Health in 
the USA published suggestions for preventing 
morbidity and mortality from SCD, from which 
we could learn several lessons and develop more 
research.16 Likewise, the Harvard study17 and the 
Sultan Qaboos University studies18,19 also offer 
some ideas which, hopefully, could stimulate the 
Oman Hereditary Blood Disorder Association and 
The Research Council to get together and do some 
similar research on SCD. Overall, we need much 
more research on this genetic disorder, like many 
other genetic disorders in Oman and in the Arab 
world.20 We have to shoulder this responsibility 
ourselves as we cannot wait for, or rely on, 
pharmaceutical companies or Western countries to 
do this research for us. Yes, we can, and we must do 
better in Oman.
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